TNFalpha Up-regulates SLUG Via the NF-kappaB/HIF1alpha Axis, Which Imparts Breast Cancer Cells with a Stem Cell-like Phenotype
Overview
Physiology
Authors
Affiliations
Extracellular and intracellular mediators of inflammation, such as tumor necrosis factor alpha (TNFα) and NF-kappaB (NF-κB), play major roles in breast cancer pathogenesis, progression and relapse. SLUG, a mediator of the epithelial-mesenchymal transition process, is over-expressed in CD44(+)/CD24(-) tumor initiating breast cancer cells and in basal-like carcinoma, a subtype of aggressive breast cancer endowed with a stem cell-like gene expression profile. Cancer stem cells also over-express members of the pro-inflammatory NF-κB network, but their functional relationship with SLUG expression in breast cancer cells remains unclear. Here, we show that TNFα treatment of human breast cancer cells up-regulates SLUG with a dependency on canonical NF-κB/HIF1α signaling, which is strongly enhanced by p53 inactivation. Moreover, SLUG up-regulation engenders breast cancer cells with stem cell-like properties including enhanced expression of CD44 and Jagged-1 in conjunction with estrogen receptor alpha down-regulation, growth as mammospheres, and extracellular matrix invasiveness. Our results reveal a molecular mechanism whereby TNFα, a major pro-inflammatory cytokine, imparts breast cancer cells with stem cell-like features, which are connected to increased tumor aggressiveness.
Understanding the role of TNFR2 signaling in the tumor microenvironment of breast cancer.
Mussa A, Ismail N, Hamid M, Al-Hatamleh M, Bragoli A, Hajissa K J Exp Clin Cancer Res. 2024; 43(1):312.
PMID: 39609700 PMC: 11603874. DOI: 10.1186/s13046-024-03218-1.
Unraveling cancer progression pathways and phytochemical therapeutic strategies for its management.
Sharma V, Chaudhary A, Bawari S, Gupta S, Mishra R, Khan S Front Pharmacol. 2024; 15:1414790.
PMID: 39246660 PMC: 11377287. DOI: 10.3389/fphar.2024.1414790.
Zingue S, Fongang Y, Ossomba E, Tatsinda V, Silihe K, Mbou W Heliyon. 2024; 10(15):e35000.
PMID: 39166076 PMC: 11334813. DOI: 10.1016/j.heliyon.2024.e35000.
Zhang Y, Kang T, Wang Y, Song C, Li H, Mi H Neuro Oncol. 2024; 26(12):2256-2271.
PMID: 39093693 PMC: 11630517. DOI: 10.1093/neuonc/noae147.
Zuo C, Xia J, Chen L Nat Commun. 2024; 15(1):5057.
PMID: 38871687 PMC: 11176411. DOI: 10.1038/s41467-024-49171-7.